Abstract:
This invention relates to a method of enhancing the stability of paricalcitol solution in a container by using a chlorobutyl or chlorinated butyl stopper in the container.
Abstract:
Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating cancer using the compounds are disclosed.
Abstract:
The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.
Abstract:
An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.
Abstract:
A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
Abstract:
The invention provides a catheter and method of making the same including an outer tubular member having a length, an outer surface, an inner surface and a lumen therein. The catheter also includes an inner tubular member having an outer surface, an inner surface and a lumen therein, at least a length of the inner lumen is disposed in the lumen of the outer tubular member. The catheter also includes a support member biasing a portion of the outer surface of the inner tubular member against a portion of the inner surface of the outer tubular member. The method of the invention includes providing a first tubular member and a second tubular member, arranging the first tubular member in contact with the second tubular member to define a contact area therebetween and joining the first and second tubular members at the contact area by irradiating them to define a fusion area having an intensity gradient.
Abstract:
An apparatus for delivering and deploying a closure element to an opening formed in a body lumen, including a delivery assembly positionable through the tissue and into the opening. The delivery assembly includes a distal locator portion and a carrier portion oriented proximal to the distal locator portion. The distal locator portion is configured to selectably engage the body lumen adjacent to the opening, and the carrier portion is configured to carry and support the closure element in a substantially tubular configuration. The carrier portion is further configured to urge the closure element toward an expanded cross-sectional dimension for deployment thereof, such that the closure element is oriented to engage the tissue when deployed and, when released, to return to the natural, substantially planar configuration and the natural cross-section dimension wherein the engaged tissue is drawn substantially closed.
Abstract:
The present invention relates to a troponin protein or complex of two troponin proteins stabilized in a matrix containing at least one anionic surfactant. The stabilized troponin or complex of troponin proteins is used as a control or calibration standard in assays for the determination of blood levels of troponin in patient samples that are expect to exhibit elevated levels of cardiac proteins. The troponin protein or complex of troponin proteins remains stabilized at room temperatures for at least six (6) months.
Abstract:
The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract:
A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.